Suppr超能文献

人乳头瘤病毒相关性口咽癌筛查的考虑因素:综述。

Considerations in Human Papillomavirus-Associated Oropharyngeal Cancer Screening: A Review.

机构信息

Department of Otolaryngology-Head and Neck Surgery, The University of Texas Southwestern Medical Center, Dallas.

Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins Medical Institutions, Baltimore, Maryland.

出版信息

JAMA Otolaryngol Head Neck Surg. 2020 Jul 1;146(7):656-664. doi: 10.1001/jamaoto.2019.4811.

Abstract

IMPORTANCE

The incidence of human papillomavirus (HPV)-positive oropharyngeal cancer (OPC) is anticipated to rise over the next few decades until the effects of prophylactic vaccination are realized, which highlights the potential importance of secondary prevention. The objective of this review is to evaluate the evidence associated with screening for HPV-positive OPC.

OBSERVATIONS

Evaluation of a potential clinical preventive screening service requires characterization of the disease burden, the at-risk target screening population, screening tests, treatment, and screening benefits and harms. The lifetime risk of OPC is 0.7% for men and 0.2% for women and is expected to increase. The disease burden of HPV-positive OPC is substantial; most patients undergo morbid multimodality treatment and incur high costs in the process. Middle-aged and older adult men with elevated number of lifetime vaginal or oral sex partners are at highest risk. Patients may benefit from early detection of the disease-the 4-year overall survival of patients with stage I HPV-positive OPC is 87%, a considerable portion of whom are eligible for less morbid single-modality therapy. However, available screening tests are insufficiently sensitive and specific considering the current HPV-positive OPC incidence rates in the most at-risk patients. Further, the benefits and harms of screening for HPV-positive OPC are unknown.

CONCLUSIONS AND RELEVANCE

The current and projected future population-level burden of HPV-positive OPC supports further exploration of secondary preventive interventions. However, screening for HPV-positive OPC is not currently justified. Advances in biomarker discovery and improved characterization of (1) a highly at-risk, target screening population and (2) the benefits and harms of screening will be necessary. Large-scale clinical trials and rigorous evaluation of how to best implement this service into clinical practice will also be needed.

摘要

重要性

预计在未来几十年内,人乳头瘤病毒(HPV)阳性口咽癌(OPC)的发病率将会上升,直到预防接种的效果显现,这凸显了二级预防的潜在重要性。本综述的目的是评估与 HPV 阳性 OPC 筛查相关的证据。

观察结果

评估潜在的临床预防筛查服务需要对疾病负担、高危目标筛查人群、筛查试验、治疗以及筛查的获益和危害进行特征描述。OPC 的终生风险为男性 0.7%,女性 0.2%,预计会增加。HPV 阳性 OPC 的疾病负担很大;大多数患者接受病态的多模式治疗,并且在此过程中产生高昂的费用。一生中阴道或口腔性行为伴侣数量较多的中老年男性风险最高。患者可能受益于早期发现疾病-Ⅰ期 HPV 阳性 OPC 患者的 4 年总生存率为 87%,其中相当一部分患者有资格接受较少病态的单一模式治疗。然而,考虑到高危患者中目前 HPV 阳性 OPC 的发病率,现有筛查试验的敏感性和特异性不足。此外,HPV 阳性 OPC 的筛查的获益和危害尚不清楚。

结论和相关性

目前和预计未来 HPV 阳性 OPC 的人群负担支持进一步探索二级预防干预措施。然而,目前不支持对 HPV 阳性 OPC 进行筛查。需要在生物标志物发现方面取得进展,并更好地描述(1)高危目标筛查人群和(2)筛查的获益和危害。还需要进行大规模的临床试验,并严格评估如何将这项服务最好地纳入临床实践。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验